摘要
1型单纯疱疹病毒(Herpes simplex virus type 1,HSV-1)感染效率高且易于通过基因工程改造,已广泛应用于肿瘤治疗研究和临床实验。溶瘤HSV-1可通过基因工程改造或从HSV-1自发突变株中筛选获得。研究证实溶瘤HSV-1能够有效抑杀肿瘤细胞,可通过多种机制靶向肿瘤细胞,溶瘤HSV-1与放化疗联合使用治疗肿瘤的研究也取得了理想的结果。目前,已有多个溶瘤HSV-1进入临床试验。
Herpes simplex virus type 1 （HSV-1） has been widely applied in the research of tumor therapy and preclinical trials because this virus is highly infectious and can be easily modified by genetic engineering. Oncolytic HSVs can be generated by genetic engineering technology or screened from spontaneous HSV-1 variants. It has been confirmed that oncolytic HSV-1 is a powerful tool to kill tumor cells, oncolytic HSVs can target tumor cells through several mechanisms, the research on combined therapy with oncolytic HSV-1 and radiotherapy （or chemotherapy） has also yielded encouraging results. At present, some oncolytic HSVs have reached clinical phase.
出处
《生命科学》
CSCD
2012年第3期236-241,共6页
Chinese Bulletin of Life Sciences
基金
国家自然科学基金项目(31140018)
新疆维吾尔自治区高校科研计划重点项目(XJEDU1010I11)
关键词
1型单纯疱疹病毒
溶瘤病毒
肿瘤治疗
Herpes simplex virus type 1
oncolytic virus
tumor therapy
